Profile of rifaximin and its potential in the treatment of irritable bowel syndrome

Natalya Iorio
Zubair Malik
Ron Schey
Section of Gastroenterology, Department of Medicine, Temple University Hospital, Philadelphia, PA, USA

Abstract: Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and abnormal bowel patterns. Alteration in gut flora, visceral hypersensitivity, and abnormal bowel motility are among numerous factors in the complex pathophysiology of IBS. Antibiotics have been used adjunctively to treat IBS for many years but are associated with various systemic side effects. Rifaximin is a nonabsorbable, broad-spectrum antimicrobial that inhibits bacterial RNA synthesis by binding the β-subunit of microbial RNA polymerase. It targets the gastrointestinal tract and works by reducing the quantity of gas-producing bacteria and altering the predominant species of bacteria present. In vivo animal studies suggest additional beneficial mechanisms of rifaximin, including reducing mucosal inflammation and visceral hypersensitivity. Clinical studies have demonstrated that rifaximin improves symptoms associated with IBS, such as bloating, flatulence, stool consistency, and abdominal pain, and has a side-effect profile similar to placebo. Although additional investigation into optimal dosing, treatment duration, and potential resistance is required, rifaximin presents as a safe and beneficial addition to the current management options for IBS.

Keywords: irritable bowel syndrome, rifaximin, small intestinal bacterial overgrowth, mucosal inflammation

Introduction
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and abnormal bowel patterns for at least 3 months. IBS is differentiated into constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), or mixed (IBS-M). Symptoms often include changes in stool frequency and consistency, flatulence, and bloating. IBS is common in the US, with an estimated prevalence of up to 20%, and negatively impacts quality of life. IBS confers a disproportionately high health care economic burden due to frequent doctor visits, repeated imaging and testing, and other diagnostic and surgical procedures.

Although the exact etiology remains unclear, important pathogenic factors are numerous: abnormal bowel motility, visceral hypersensitivity, neurotransmitter imbalance, infection, inflammation, brain–gut interaction, and psychosocial stress. Nearly 10% of patients with an intestinal bacterial infection report postinfectious symptoms up to 10 years after the infectious event. Recent studies have identified the role of bacteria in maintaining normal gut function, including protection against pathogens, metabolism, and absorption. In addition, they demonstrated an increased quantity and alteration in the type and distribution of gut bacterial flora in patients with IBS. Previous studies have demonstrated less lactobacilli, coliforms, and bifidobacteria...
have been reported among IBS patients compared to healthy controls, while previous studies have found no difference in the total quantity of bifidobacteria. Varying bacterial load can correlate to subgroups of IBS, such as less Lactobacilli spp. in IBS-D and more Veillonella spp. in IBS-C. Studies of fecal microbiota in IBS patients have been somewhat inconsistent and likely confounded by diet, obesity, age, gut transit, antibiotic use, and genetic factors.

Hydrogen and methane produced by the bacterial fermentation of unabsorbed carbohydrates in the gastrointestinal tract are excreted and detected by breath testing. Breath testing is commonly used to diagnose lactose, fructose, or sorbitol malabsorption; small intestinal bacterial overgrowth (SIBO); and delayed gut transit. A higher concentration of gas-producing bacteria and greater level of organic acid have been shown to correlate with severity of functional gastrointestinal symptoms, such as abdominal discomfort, distention, and flatulence. SIBO, characterized by abnormally elevated levels of colonic bacteria (>10^9 colony-forming units/mL) in the small intestine, has also been associated with IBS symptoms, although a direct relationship has not been established and the evidence is conflicting. The quantitative change in the bacterial concentration in the small bowel seen in SIBO and IBS disrupts normal gut function, including digestion and absorption. In SIBO, bacterial production of short-chain fatty acids leads to increased colonic motility but decreased motility in the proximal intestine. Gut dysmotility and distention from increased bacterial fermentation and gas production are common to the pathophysiology of both disorders. A high proportion of IBS patients have an abnormal lactulose breath test (45%–84%) and symptom improvement following antibiotic treatment. This suggests a strong overlap between bacterial overgrowth and IBS. However, the prevalence of SIBO in IBS patients varies significantly depending on the diagnostic criteria used (lactulose breath test, glucose hydrogen breath test, or jejunal aspirate test). Additionally, bacterial infectious gastroenteritis is a significant risk factor for the development of IBS.

Treatment for IBS remains an ongoing clinical challenge. Current therapies include antispasmodics, prosecretory agents such as linaclotide and lubiprostone, peppermint oil, antidepressants, and psychotherapy. Prior studies have shown that broad-spectrum antibiotics, such as tetracycline, amoxicillin-clavulanate, metronidazole, neomycin, and fluoroquinolones, can improve bowel symptoms presumably through their ability to decrease bacterial overgrowth. In a prospective, randomized, controlled trial of 111 subjects, neomycin was more effective than placebo in improving a composite score calculated based on abdominal pain, diarrhea, and constipation symptoms; ≥50% improvement was determined to be by the clinical response. In a retrospective study that evaluated the effect of antibiotics on IBS symptoms, initial treatment with neomycin and other antibiotics (excluding rifaximin) produced a clinical response, similarly defined as >50% symptom improvement, in only 38% and 44% of patients, respectively. The symptoms rated included bloating, diarrhea, constipation, and abdominal pain. Retreatment with doxycycline, neomycin, or amoxicillin/clavulanate was ineffective in a majority of patients (75%) and demonstrated evidence of clinical resistance. Also, readily absorbable oral antibiotics bear the relevant drawback of associated systemic side effects. This review discusses the clinical use of rifaximin, a nonabsorbable, gut-targeted antimicrobial, in the management of IBS.

**Mechanism of action**

Rifaximin (xifaxan; Salix Pharmaceuticals, Inc., Raleigh, NC, USA) is an oral semisynthetic derivative of rifamycin with antimicrobial activity against Gram-positive and Gram-negative aerobic and anaerobic organisms. Pistiki et al demonstrated the in vitro effect of rifaximin using duodenal aspirates with quantitative cultures for diagnosing SIBO. Minimal inhibitory concentrations and time-kill assays showed inhibition of small bowel flora associated with SIBO, including 85% of Escherichia coli, 44% of Klebsiella, 35% of Enterobacter, 82.6% of other Gram-negative species, 100% of Enterococcus faecalis, 100% of Enterococcus faecium, and 100% of Staphylococcus aureus. Rifaximin produced a >3log decrease after 24 hours of growth at concentrations of only 500 µg/mL, which is significantly less than the reported stool concentrations of 8,000 µg/mL. Treatment with rifaximin is also effective against enteric protozoal infections, including Cryptosporidium and Blastocystis.

Rifaximin binds the β-subunit of microbial RNA polymerase, thereby inhibiting transcription and RNA synthesis. Rifaximin acts locally within the gastrointestinal tract and has negligible absorption (<0.01% detected in plasma) after oral administration. Less than 0.01% of the unchanged medication is excreted in the urine. Therefore, there is minimal risk of toxicity or systemic side effects. However, the bioavailability of rifaximin varies throughout the gastrointestinal tract based on its hydrophobic properties and insolubility in water. Solubility of the drug increases 100-fold in the presence of bile acids, which suggests that its antimicrobial effect is primarily achieved in the small bowel and less so in the colon.
Xu et al hypothesized a multifactorial mechanism of rifaximin in the improvement of symptoms in IBS.29 Using a rat model for visceral hyperalgesia, they measured visceral-motor response to colorectal distension, gut permeability, and microbial DNA in the ileum and found that oral rifaximin decreased the overall quantity of bacteria and altered the bacterial composition in the ileum with a higher relative abundance of Lactobacillus species. Rifaximin decreased mucosal inflammation, measured by decreased levels of interleukins (IL-17 and IL-6) and tumor necrosis factor α (TNF-α) as well as visceral pain in response to chronic stress psychological.29 In addition, neomycin did not decrease visceral pain in response to colon distension and did not prevent the elevation in IL-17, IL-6, or TNF-α.26 The amount of fermentation and gas production is reduced mainly by lessening the bacterial load, particularly in the colon, which is a likely key component in reducing bloating, flatulence, and abdominal discomfort caused by bowel distention.30 It is unclear whether changing the predominant species of gut flora may confer relief due to inadequate studies and inconclusive data regarding the effect of probiotics.31 More recent studies also suggest that rifaximin may reverse chronic stress-induced mucosal inflammation and epithelial dysfunction, and the effect is accompanied by an increase in Lactobacillus and a decrease in segmented filamentous bacteria.32

Rifaximin appears to impede the ability of enteric pathogens to adhere to epithelial cells and internalize, or invade, the host cells. Epithelial cells treated with rifaximin exhibited reduced enteroaggregative E. coli adherence as well as decreased attachment and translocation of Bacillus anthracis or Shigella sonnet.33 IBS patients have been shown to have altered microbiota and an associated increase in mucosal inflammation and dysregulation of the host immune response. Also, there may be an impairment in the epithelial barrier and increased permeability.34 In addition to reducing the harmful proinflammatory effects of bacterial mucosal invasion, rifaximin likely produces a direct antiinflammatory effect as well. Rifaximin acts as an agonist to human pregnane X receptor (PXR) in the gut intestinal epithelial cells, which regulates the expression of cytokines and chemokines via toll-like receptor (TLR)-4 and NF-kappa B (NF-κB) pathways. Rifaximin also suppresses the binding of NF-κB triggered by bacterial endotoxin through the activation of PXR and induces TGF-β, and thus, helps to maintain immune homeostasis.35

**Rifaximin use in IBS**

In a randomized double-blind placebo-controlled trial of 124 patients with functional gastrointestinal symptoms, Sharara et al studied the efficacy of rifaximin 400 mg twice daily vs placebo for 10 days on IBS and non-IBS patients (Table 1).36 All patients met inclusion criteria of at least 12 weeks of active symptoms, including bloating, excessive flatulence and chronic abdominal pain and discomfort, disturbances in bowel movements, feeling of incomplete evacuation, or abnormal stool consistency. Patient follow-up was for a total of 30 days (10 days in pretreatment baseline phase, 10 days in the treatment phase, and 10 days in the posttreatment phase). Patients recorded daily symptoms, including abdominal pain, distension, frequency of bowel movements, stool consistency, and feeling of incomplete evacuation. Rifaximin produced significant improvement in global symptom relief compared to placebo (41.3% vs 22.9%, P=0.03) in the subset of IBS-positive patients (40.5% vs 18.2%, P=0.04). Treatment with rifaximin was also associated with improvement in abdominal bloating, distension, and flatulence. Improvement in bloating score correlated with a decrease in hydrogen production on lactulose breath testing among responders to rifaximin (R=0.631), but no significant correlation was found between nonresponders (R=0.227).36

Meyrat et al evaluated the efficacy of rifaximin among IBS patients in daily clinical practice as well as assessed the prevalence of positive lactulose hydrogen breath test. They treated 106 of 150 (71%) IBS patients with a positive breath test using 200 mg of rifaximin four times per day for 14 days. Patients rated their symptoms at baseline, week 4, and week 14. The 11-point Likert scale was used to measure the severity of symptoms and overall well-being (0—no symptoms or no change in the overall well-being and 10—most severe symptoms and severe reduction in the overall well-being). IBS patients with a positive breath test reported more severe bloating (5.5% vs 4.6%, P=0.028) and diarrhea (2.9% vs 2.2%, P=0.026) at baseline compared to IBS patients with a negative lactulose breath test. They found a significant improvement in the following IBS-related symptoms, comparing scores at baseline with scores after 4 weeks of rifaximin treatment: bloating (5.5% vs 3.6%, P<0.01), flatulence (5.0% vs 4.1%, P=0.01), diarrhea (2.9% vs 2.0%, P<0.01), abdominal pain (4.8% vs 3.3%, P<0.01), and overall well-being (3.9% vs 2.7%, P<0.01). In a cohort undergoing repeat breath testing, a negative test at 4 weeks was reported in 55 of 64 (86%) patients. Interestingly, those patients who remained positive for lactulose hydrogen breath test reported no change in symptoms between week 0 and week 4.35

More recently, Pimentel et al described two identically designed, Phase III, double-blind, randomized, multicenter,
Table 1: Studies of rifaximin in patients with IBS

| Study and design | No of participants | Primary and secondary outcomes | Rifaximin dose and duration | Results | Limitations |
|------------------|--------------------|--------------------------------|-----------------------------|---------|-------------|
| Sharara et al10 | N=124 | Primary: global IBS symptom improvement<br>Secondary: change in LHBT, composite 10-day symptom score | 400 mg bid for 10 days | Higher global improvement in IBS symptoms with rifaximin (41.3% vs 22.9%, P=0.03). Lower mean symptoms score and bloating with rifaximin (P=0.01). No significant change in LHBT overall with rifaximin. Significant drop in LHBT in responders to rifaximin vs non-responders, and correlated with bloating and overall symptom scores (P=0.01) | Only 54% and 59% of participants in each group fulfilled Rome II criteria for IBS; single center |
| Pimentel et al10 | N=87 | Primary: global IBS symptoms<br>Secondary: abdominal pain, bloating, diarrhea, and constipation | 400 mg tid for 10 days | Higher global improvement in IBS symptoms with rifaximin (36.4% vs 21%, P=0.02). Bloating improved with rifaximin (P=0.01). Abdominal pain, diarrhea, and constipation were not significantly different | Most patients were from a single center; short duration |
| Meyrat et al13 | N=106 | LHBT Overall well-being, bloating, diarrhea, flatulence, and abdominal pain | 200 mg qid for 14 days | 71% were LHBT positive<br>Improved overall well-being (3.9% vs 2.7%, P<0.001), bloating (5.5% vs 3.6%, P<0.001), flatulence (5% vs 4%, P=0.015), diarrhea (2.9% vs 2%, P=0.005), and abdominal pain (4.8% vs 3.3%, P<0.001) | Lack of control group; unblinded |
| Pimentel et al37 | N=1,260 | Primary: global IBS symptom relief for at least 2 of 4 weeks<br>Secondary: adequate relief of bloating, abdominal pain, and discomfort | 550 mg tid for 14 days | Higher global improvement in IBS symptoms with rifaximin (40.8% vs 31.2%, P=0.01, TARGET 1; 40.6% vs 32.2%, P=0.03, TARGET 2; and 40.7% vs 31.7%, P<0.001, combined). Rifaximin group had more relief of bloating (39.5% vs 28.7%, P=0.005, TARGET 1; 41.0% vs 31.9%, P=0.02, TARGET 2; and 40.2% vs 30.3%, P<0.001, combined) and abdominal pain/discomfort (44.3% vs 36.3%, P=0.03, TARGET 1 and 42.9% vs 34.4%, P=0.02, TARGET 2) | Only included IBS without constipation |
| Pimentel et al38 | N=31 | Primary: constipation severity<br>Secondary: overall constellation severity, straining, bloating, and abdominal pain | Neomycin (500 mg bid) + placebo<br>Neomycin 500 mg bid and rifaximin (550 mg tid) for 14 days | Lower constipation severity with addition of rifaximin (28.6 mm vs 61.2 mm, P=0.0042). Greater improvement in straining (P=0.017) and bloating (P=0.020), but not abdominal pain | IBS-C only; combined systemic and non-absorbable antibiotics |

Abbreviations: IBS, irritable bowel syndrome; No, number; P, prospective; R, randomized; DB, double blind; PC, placebo controlled; LHBT, lactulose hydrogen breath test; bid, twice daily; tid, three times a day; qid, four times a day; TARGET, targeted, nonsystemic antibiotic rifaximin gut-selective evaluation of treatment for non-c irritable bowel syndrome; IBS-C, constipation-predominant IBS.
placebo-controlled trials (targeted, nonsystemic antibiotic rifaximin gut-selective evaluation of treatment for non-c irritable bowel syndrome [TARGET], [TARGET] 1 and TARGET 2) of 1,260 IBS patients, diagnosed by Rome II criteria, without constipation. The study compared rifaximin 550 mg three times a day vs placebo for 14 days. Patients were assessed for an additional 10-week period after treatment. The primary outcome measured was relief of global IBS symptoms determined by a weekly yes or no response to the question, “In regard to all your symptoms of IBS, as compared with the way you felt before you started the study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms”? Secondary end points were self-reported symptomatic relief of bloating and abdominal pain (Figure 1). More patients in the rifaximin group related adequate improvement of global IBS symptoms (40.8% vs 31.2%, \( P=0.01 \), in TARGET 1; 40.6% vs 32.2%, \( P=0.03 \), in TARGET 2; and 40.7% vs 31.7%, \( P<0.001 \), combined). Treatment with rifaximin also resulted in significantly higher relief of IBS-related bloating for >2 weeks after treatment (39.5% vs 28.7%, \( P=0.005 \), in TARGET 1; 41.0% vs 31.9%, \( P=0.02 \), in TARGET 2; and 40.2% vs 30.3%, \( P<0.001 \), combined). A significantly higher proportion of patients in the rifaximin group also reported greater improvement in abdominal pain or discomfort and loose or watery stools (46.6% vs 38.5%, \( P=0.04 \), in TARGET 1 and 46.7% vs 36.3%, \( P=0.008 \), in TARGET 2). The incidence of adverse events (AEs) was similar among both groups (1.6% vs 2.4%), and no case of Clostridium difficile-associated diarrhea or ischemic colitis was reported.\(^{37}\)

In another study by Pimentel et al, the potential use of rifaximin was extended to IBS-C. This double-blind, randomized, placebo-controlled trial compared the adjunctive use of rifaximin with neomycin vs neomycin alone in 31 patients aged 18–65 years who fulfilled Rome II criteria for IBS-C. Inclusion criteria were less than three complete and spontaneous bowel movements per week and breath methane >3 ppm. Exclusion criteria included use of antibiotic or probiotic within 30 days and use of narcotics, proton pump inhibitors, tricyclic antidepressants, or other bowel-altering medications. Patients were treated with 500 mg neomycin twice daily and 550 mg rifaximin three times a day for 14 days or neomycin alone. Weekly symptom questionnaires were filled out using a visual analog scale (0 – no symptoms and 10 – severe symptoms) to assess abdominal pain, constipation, bloating, urgency, incomplete evacuation, straining, and diarrhea. They reported a significant improvement in the primary outcome, severity of constipation (28.6 mm vs 61.2 mm, \( P=0.0042 \), as well as secondary outcomes (straining and bloating) with the adjunctive use of rifaximin. This therapeutic gain continued up to 4 weeks post treatment. However, they did not find an improvement in abdominal pain. Lower methane levels following treatment were associated with improved symptoms. Both groups had a similar proportion of subjects with methane levels ≤3 ppm after treatment: ten out of 15 subjects receiving adjuvant rifaximin and eleven out of 16

Figure 1 Percentage of patients with relief of symptoms during the primary evaluation period (weeks 3–6).

**Note:** Rifaximin 550 mg or placebo three times daily.

**Abbreviation:** IBS, irritable bowel syndrome.
subjects receiving neomycin alone. In the neomycin and rifaximin groups, subjects with methane ≤ 3 ppm after treatment reported significantly lower constipation severity than subjects with persistent methane (P=0.02). It is important to mention that Salix Pharmaceuticals, the manufacturer of rifaximin, supported this trial.

Given the chronicity of IBS and probable necessity of patients requiring repeated rifaximin treatments, Pimentel et al reported that >75% of subjects who initially responded to rifaximin also responded to further retreatment with no significant reduction in benefit with successive treatments. Furthermore, there was no change in the duration of benefit (median time between treatments) of successive retreatments. Yu et al studied orocecal transit time using scintigraphy and concluded that the abnormal lactulose breath test in IBS patients can be explained by variation in gut transit time and not necessarily SIBO.

**Additional clinical use**

Rifaximin is currently used for a variety of gastrointestinal-related conditions such as infectious diarrhea, hepatic encephalopathy, SIBO, inflammatory bowel disease, and diverticular disease. However, approval by the US Food and Drug Administration is limited to traveler’s diarrhea caused by non-invasive E. coli in patients aged 12 years or older and prevention of hepatic encephalopathy in adults. The proposed mechanism by which rifaximin, like other antibiotics, improves hepatic encephalopathy is by decreasing the amount of ammonia-producing bacteria in the gastrointestinal tract. Studies have shown that treatment with rifaximin successfully decreases the frequency of hepatic encephalopathy episodes and hospitalizations. In a meta-analysis of 19 randomized controlled trials encompassing 1,370 patients, treatment with rifaximin was significantly more effective than placebo in the secondary prevention of hepatic encephalopathy and in promoting recovery from hepatic encephalopathy. More importantly, rifaximin was shown to reduce mortality (relative risk: 0.68, 95% CI 0.48–0.97).

More recently, investigators have been exploring new potential applications for rifaximin, particularly in gastrointestinal-related conditions. There is some preliminary data that rifaximin, both as monotherapy and adjuvant therapy, can be effective in producing clinical improvement and remission in patients with inflammatory bowel disease. The use of rifaximin to treat C. difficile-associated diarrhea has also shown promising results. Several small, uncontrolled studies have reported efficacy between 64% and 79% in patients with recurrent disease unresponsive to first-line therapy.

In a retrospective review of 32 patients with recurrent C. difficile infection having undergone prior antibiotic courses with a mean of 4.4, 17 of the 32 patients (53%) had no relapse 3 months post treatment with rifaximin. Utilizing the beneficial properties such as lack of absorption and broad spectrum of activity, the clinical application of rifaximin has been extended beyond the gastrointestinal tract. Topical formulations of rifaximin to treat skin infections, periodontal disease, and bacterial vaginosis are currently being developed and studied.

**Safety**

Rifaximin has been shown to be safe and well tolerated with no more increased risk of AEs than placebo. A post hoc analysis of Phase IIb and Phase III trials performed in the US and Canada demonstrated comparable rates of drug-related AEs (12.1% vs 10.7%) between rifaximin (n=1,103) and placebo (n=829). The safety assessments included overall AEs, serious AEs, events resulting in study discontinuation, gastrointestinal-associated AEs, and infection-related AEs and were not substantially different with the use of rifaximin. The majority of AEs were mild–moderate and most commonly gastrointestinal related with similar occurrences in the rifaximin and placebo groups (nausea: 4.4% vs 3.7%, abdominal pain: 3.7% vs 4.7%, diarrhea: 3.4% vs 3.1%, and vomiting: 2.0% vs 1.4%). There was no increased risk of infection, including C. difficile. A different study of 106 patients undergoing rifaximin treatment reported infrequent side effects of headache (3%), dry skin (1%), and nausea without vomiting (1%). However, this was not a placebo-controlled trial, and it is unclear if these were drug-related side effects. In the larger study by Pimentel et al, a safety analysis included 1,258 subjects (624 in the rifaximin group and 634 in the placebo group). The risk of serious AEs was less in the rifaximin group than in the placebo group (1.6% vs 2.4%), and there were no cases of C. difficile, ischemic colitis, or death. Rifaximin is not known to have significant drug interactions; however, it should be used with caution in patients with Child-Pugh class C cirrhosis.

A recent study compared generic and branded formulations of rifaximin and found significant differences in systemic bioavailability. Plasma drug concentrations were higher after administration of generic rifaximin compared to branded formulation that contains the polymorph rifaximin-α, which has limited bioavailability. This variance was attributed to drug polymorphisms and inherent differences between crystalline and amorphous forms of the compounds. It is important to emphasize these differences as different
formulations are produced and the potential for dosing and the development of systemic effects changes.

Conclusion

There is cumulative data that rifaximin is a safe and effective addition to the current armamentarium of treatment for IBS. Rifaximin has been shown to improve global IBS symptoms, such as bloating, flatulence abdominal pain, and stool consistency. As a nonabsorbable antimicrobial drug, it targets the gastrointestinal tract with minimal systemic effects. The American College of Gastroenterology issued an evidence-based statement that rifaximin is effective in reducing total IBS symptoms as well as bloating in IBS-D; however, the level of evidence supporting this statement is moderate, and the authors emphasize that further research is needed.

A large proportion of IBS patients have been shown to have SIBO based on a positive lactulose hydrogen breath testing, and this may correlate with severity of symptoms. Additionally, studies have suggested an association between IBS and SIBO, with antibiotics such as rifaximin or neomycin resulting in improvement. However, the relationship appears to be inconsistent with dramatic heterogeneity between different types of tests. Interestingly, in non-IBS patients presenting with bloating and flatulence and positive lactulose hydrogen breath testing, treatment with rifaximin was only successful (defined as normalization of breath test) in 42% of subjects. This finding supports the concept of a multifaceted benefit of rifaximin in treating IBS beyond simply SIBO eradication.

Thus far, there is a variation in medication dose and length of treatment between all mentioned clinical trials. Further investigation is needed to establish a standard dose and duration. Although rifaximin is superior to placebo, the symptom–response curve suggests some loss of efficacy toward the end of the 10-week follow-up periods. Given the chronicity of IBS, additional studies to date are needed to determine if a similar effect can be seen with subsequent therapy. Additionally, it is important to recognize the significant cost of rifaximin treatment. Costing approximately $21.6 per day (at a dose of 400 mg three times per day), it is comparatively more expensive than other antibiotics, for instance, $3.6 for a month of neomycin. Cost–benefit analysis of rifaximin use for the treatment of hepatic encephalopathy, but not for IBS, has noted rifaximin as being the most effective yet most expensive therapy, and recommended rifaximin salvage therapy after other less-expensive measures fail as a more cost-effective alternative. Future studies analyzing the cost–benefit of rifaximin for the treatment of IBS would be helpful in guiding clinical management. Other important outcomes such as risk of C. difficile infection or antibiotic resistance will need to be further assessed. Although future studies will be required to determine the long-term safety and efficacy of rifaximin, it emerges as a safe and beneficial addition to the current management option for IBS.

Author contributions

Ron Schey is the guarantor of this article. Natalya Iorio reviewed the medical literature and contributed to drafting the manuscript. Zubair Malik contributed to drafting the manuscript. Ron Schey initiated and contributed to drafting the manuscript and final edits. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work. All authors approved the final draft submitted.

Disclosure

The authors report no funding and no conflicts of interest in this work.

References

1. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl 1):S1–S35.
2. Horwitz B, Fisher RS. The irritable bowel syndrome. N Engl J Med. 2001;344(24):1846–1850.
3. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122(6):1701–1714.
4. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am. 2011;40(1):11–19.
5. Schwille-Kiuntke J, Enck P, Zendler C, et al. Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil. 2011;23(11:e479–e488.
6. Bolino CM, Bercik P. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Infect Dis Clin North Am. 2010;24(4):961–975, ix.
7. Esposito I, de Leone A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13(45):6016–6021.
8. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24–33.
9. Balsari A, Cecarelli A, Dubini F, Fesco E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologia. 1982;5(3):185–194.
10. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100(2):373–382.
11. Rana SV, Malik A. Breath tests and irritable bowel syndrome. World J Gastroenterol. 2014;20(24):7587–7601.
12. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5):512–519, e114–e115.
13. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2009;7(12):1279–1286.

14. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. *World J Gastroenterol*. 2014;20(10):2482–2491.

15. Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. *Aliment Pharmacol Ther*. 2012;36(11–12):1084–1093.

16. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. *Am J Gastroenterol*. 2003;98(2):412–419.

17. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritative bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. *Dig Dis Sci*. 2006;51(8):1297–1301.

18. Futagami S, Itoh T, Sakamoto C. Systematic review with meta-analysis: post-infectious functional dyspepsia. *Aliment Pharmacol Ther*. 2015;41(2):177–188.

19. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *Am J Gastroenterol*. 2014;109(Suppl 1):S2–S26; quiz S7.

20. Basseri RJ, Weitsman S, Barlow GM, Pimentel M. Antibiotics for the treatment of irritable bowel syndrome. *Gastroenterol Clin North Am*. 2011;40(4):493–506.

21. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. *Dig Dis Sci*. 2008;53(1):169–174.

22. Scarpignato C, Pelosi I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. *Chemotherapy*. 2005;51(Suppl 1):36–66.

23. Pistiaki A, Galani I, Pyleris E, Barbatzas C, Pimentel M, Gianarellos-Bourboulis EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. *Int J Antimicrob Agents*. 2014;43(3):236–241.

24. Amenta M, Dalle Nogare ER, Colomba C, et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in *Cryptosporidium parvum* and *Blastocystis hominis* infections. *J Chemother*. 1999;11(5):391–395.

25. Umezawa H, Mizuno S, Yamazaki H, Nitta K. Inhibition of DNA-directed RNA synthesis by rifamycins. *J Antibiot*. 1968;21(3):234–236.

26. Rivkin A, Sim S. Rifaximin: new therapeutic indication and future directions. *Clin Ther*. 2011;33(7):812–827.

27. Laterza L, Ianigo G, Scolieri I, et al. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. *Expert Opin Pharmacother*. 2015;16(4):607–615.

28. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. *Int J Clin Pharmacol Res*. 1994;14(2):51–56.

29. Xu D, Gao J, Gililand M 3rd, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. *Gastroenterology*. 2014;146(2):484–496.

30. Schey R, Rao SS. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. *Expert Rev Gastroenterol Hepatol*. 2011;5(4):461–464.

31. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. *Am J Gastroenterol*. 2009;104(4):1033–1049; quiz 50.

32. Gao J, Gilliland MG 3rd, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. *Gut Microbes*. 2014;5(4):571–575.

33. Brown EL, Xue Q, Jiang ZD, Xu Y, Dupont HL. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. *Antimicrob Agents Chemother*. 2010;54(1):388–396.

34. Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. *World J Gastroenterol*. 2014;20(27):8886–8897.

35. Mencarelli A, Renga B, Palladino G, et al. Inhibition of NF-kappaB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. *Eur J Pharmacol*. 2011;668(1–2):317–324.

36. Sharara AI, Aoun E, Abdal-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. *Am J Gastroenterol*. 2006;101(2):326–333.

37. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. *N Engl J Med*. 2011;364(1):22–32.

38. Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. *Dig Dis Sci*. 2014;59(6):1278–1285.

39. Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. *Dig Dis Sci*. 2011;56(7):2067–2072.

40. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. *Gut*. 2011;60(3):334–340.

41. Cotteau J, Baker SF, DuPont HL, Carey KW. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. *Expert Rev Anti Infect Ther*. 2010;8(7):747–760.

42. Kimer N, Krag A, Moller S, Bendtsen F, Glund LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. *Aliment Pharmacol Ther*. 2014;40(2):123–132.

43. Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. *World J Gastroenterol*. 2011;17(2):4643–4646.

44. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent *Clostridium difficile* infection. *Aliment Pharmacol Ther*. 2013;37(1):122–128.

45. Pelosi I, Scarpignato C. Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. *Chemotherapy*. 2005;51(Suppl 1):122–130.

46. Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. *Aliment Pharmacol Ther*. 2014;39(10):1161–1168.

47. Blandizzi C, Viscomi GC, Marco A, Scarpignato C. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. *Pharmacol Res*. 2014;85:39–44.

48. Böttin D, Perets T, Shporn E, et al. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. *Ann Clin Microbiol Antimicrob*. 2014;13:49.

49. Huang E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy – a decision analysis. *Aliment Pharmacol Ther*. 2007;26(8):1147–1161.

50. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. *Ann Intern Med*. 2006;145(8):557–563.
